← Back to Screener
Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO)
Price$4.58
Favorite Metrics
Price vs S&P 500 (26W)36.65%
Price vs S&P 500 (4W)-10.79%
Market Capitalization$268.03M
All Metrics
Book Value / Share (Quarterly)$1.11
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)111.68%
Cash Flow / Share (Quarterly)$-0.87
Price vs S&P 500 (YTD)6.22%
Gross Margin (TTM)99.43%
Net Profit Margin (TTM)-157.40%
EPS (TTM)$-1.29
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$-1.29
Revenue Growth (5Y)42.49%
EPS (Annual)$-1.10
ROI (Annual)-67.87%
Gross Margin (Annual)99.43%
Net Profit Margin (5Y Avg)-1115.45%
Cash / Share (Quarterly)$1.87
Revenue Growth QoQ (YoY)12120.16%
ROA (Last FY)-45.88%
Revenue Growth TTM (YoY)1169.22%
EBITD / Share (TTM)$-1.08
ROE (5Y Avg)-227.70%
Operating Margin (TTM)-154.73%
Cash Flow / Share (Annual)$-0.87
P/B Ratio4.23x
P/B Ratio (Quarterly)3.70x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)7.40x
Net Interest Coverage (TTM)-57.95x
ROA (TTM)-65.56%
EPS Incl Extra (Annual)$-1.10
Current Ratio (Annual)6.45x
Quick Ratio (Quarterly)6.37x
3-Month Avg Trading Volume0.20M
52-Week Price Return60.14%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)8.01x
Asset Turnover (Annual)0.29x
52-Week High$5.42
Operating Margin (5Y Avg)-1154.70%
EPS Excl Extra (Annual)$-1.10
CapEx CAGR (5Y)-1.96%
26-Week Price Return45.40%
Quick Ratio (Annual)6.37x
13-Week Price Return2.69%
Total Debt / Equity (Annual)0.23x
Current Ratio (Quarterly)6.45x
Enterprise Value$247.604
Revenue / Share Growth (5Y)31.23%
Asset Turnover (TTM)0.42x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.79x
Pretax Margin (Annual)-157.40%
Cash / Share (Annual)$1.87
3-Month Return Std Dev64.63%
Gross Margin (5Y Avg)95.31%
Net Income / Employee (TTM)$-1
ROE (Last FY)-83.15%
Net Interest Coverage (Annual)-31.02x
EPS Basic Excl Extra (Annual)$-1.10
Receivables Turnover (TTM)358.10x
Total Debt / Equity (Quarterly)0.23x
EPS Incl Extra (TTM)$-1.29
Receivables Turnover (Annual)358.10x
ROI (TTM)-116.17%
P/S Ratio (TTM)8.01x
Pretax Margin (5Y Avg)-1115.45%
Revenue / Share (Annual)$0.70
Price vs S&P 500 (52W)25.05%
Year-to-Date Return10.36%
5-Day Price Return6.51%
EPS Normalized (Annual)$-1.10
ROA (5Y Avg)-76.56%
Net Profit Margin (Annual)-157.40%
Month-to-Date Return7.76%
EBITD / Share (Annual)$-1.08
Operating Margin (Annual)-154.73%
LT Debt / Equity (Annual)0.23x
ROI (5Y Avg)-99.22%
LT Debt / Equity (Quarterly)0.23x
EPS Basic Excl Extra (TTM)$-1.29
P/B Ratio (Annual)3.70x
Inventory Turnover (TTM)0.79x
Pretax Margin (TTM)-157.40%
Book Value / Share (Annual)$1.11
Price vs S&P 500 (13W)-0.17%
Beta0.64x
Revenue / Share (TTM)$0.54
ROE (TTM)-169.64%
52-Week Low$2.20
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.07
4.07
4.07
4.07
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
OBIOOrchestra BioMed Holdings, Inc. Ordinary Shares | 8.01x | 42.49% | 99.43% | -154.73% | $4.58 |
SYKStryker Corporation | 5.24x | 11.84% | 64.57% | 19.43% | $343.32 |
BSXBoston Scientific Corp. | 4.75x | 15.16% | 69.01% | 18.00% | $64.23 |
MMM3M Company | 3.26x | -4.97% | 39.92% | 18.55% | $154.55 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $47.64 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.54 |
RMDResMed Inc. | 6.16x | 11.72% | 60.85% | 33.70% | $228.12 |
DXCMDexCom, Inc. | 5.28x | 19.33% | 62.09% | 19.56% | $63.98 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $273.73 |
PODDInsulet Corporation | 5.30x | 24.53% | 71.63% | 12.92% | $203.73 |
PENPenumbra, Inc. | 9.30x | 20.16% | 67.14% | 13.48% | $332.13 |
About
Orchestra BioMed Holdings Inc is a biomedical company that develops innovative medical device technologies through strategic partnerships with established device manufacturers. The company's flagship products include BackBeat Cardiac Neuromodulation Therapy for treating hypertension and Virtue Sirolimus AngioInflusionBalloon for treating atherosclerotic artery disease. Its partnership-enabled model reduces development risk by sharing the burden with commercialization partners while accelerating time to market for its product candidates.